Amedisys (AMED) Tops Q3 EPS by 18c, Raises FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Amedisys Reports Third Quarter 2018 Financial Results and Updates 2018 Guidance
October 29, 2018 5:00 PM EDTBATON ROUGE, La., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month period ended September 30, 2018.
Three Month Periods Ended September 30, 2018 and 2017
Net service revenue increased $43.6Â million to $417.3Â million compared to $373.7Â million in 2017 (1).Net income attributable to Amedisys, Inc. of $31.4Â million compared to $14.6Â million in 2017.Net income attributable to Amedisys, Inc. per diluted share of $0.96 per diluted share compared to $0.42 in 2017.Adjusted Quarterly Results*
Adjusted EBITDA of $45.3Â million compared to $36.9Â million in 2017.Adjusted net service... More


